Medline Industries has officially launched the year’s most anticipated initial public offering, raising $6.26 billion and marking the largest IPO globally in 2025. The Illinois-based medical supplies giant priced its offering at $29 per share on December 16, with shares now trading on the Nasdaq under the symbol MDLN.
🔥 Quick Facts
- Medline raised $6.26 billion in the largest global IPO of 2025, surpassing previous record expectations.
- The 179 million shares were priced at $29 each, positioned near the top of the initially targeted $26-$30 range.
- Medline Inc. trades on Nasdaq Global Select Market under ticker MDLN with approximately $39 billion market value at IPO pricing.
- The company generated $25.5 billion in net sales during 2024, with 43,000 employees worldwide serving healthcare institutions.
Medline IPO Marks Historic PE Exit in Healthcare
Intuit emerges as best software stock for 2026 while stock crashes to bargain levels analysts didn’t expect
2026 tax brackets shock Americans with hidden paycheck truth nobody expected
Three leading private equity firms orchestrated Medline’s return to public markets after a transformative four-year partnership. Blackstone, Carlyle Group, and Hellman & Friedman had acquired a majority stake in Medline through a landmark $34 billion leveraged buyout in 2021, which was one of the largest LBOs since the financial crisis.
Today’s IPO represents a significant partial exit for these PE backers, allowing them to unlock tremendous value while maintaining stakes in the company. The gross proceeds of $6.26 billion exceed most initial projections, reflecting investor confidence in the healthcare sector and Medline’s resilient business model during uncertain economic times.
Understanding Medline’s Market Position and Scale
Marcus Lemonis takes CEO role at Bed Bath & Beyond with $25M cost-cutting plan and watch what industry experts are saying about his next move
SPX surges 34 points at open with shocking tech recovery, here’s what caused the unexpected Venezuela rally
Medline Industries ranks among the largest manufacturers and distributors of medical supplies globally, supplying hospitals, physicians’ offices, and healthcare facilities with critical products. The company’s portfolio spans surgical gloves, protective gowns, examination tables, and thousands of other essential medical supplies that drive daily healthcare operations worldwide.
The Illinois-based distributor demonstrated consistent growth trajectory since its latest acquisition. Between 2022 and 2024, the company expanded net sales by 20 percent, growing from $21.45 billion to $25.5 billion. During the first half of 2025, Medline posted $13.5 billion in net sales, reflecting 9.8 percent year-over-year growth and profitable operations that appeal to institutional investors.
| Financial Metric | Details |
| IPO Proceeds (Gross) | $6.26 billion |
| IPO Proceeds (Net) | ~$5.6 billion (after underwriting fees) |
| Share Price at Offering | $29 per share |
| Market Capitalization at IPO | ~$39 billion to $54.5 billion |
| 2024 Net Sales | $25.5 billion |
| H1 2025 Net Sales | $13.5 billion |
Why Medline’s IPO Defied Market Skepticism and Delivered Results
Healthcare remains a resilient sector even during economic uncertainty, and Medline’s proven track record made investors confident. Unlike consumer-discretionary IPOs or speculative tech offerings, Medline provides essential supplies that healthcare providers must purchase regardless of economic cycles. The company already generates substantial profits and cash flow, eliminating concerns about years of losses before reaching profitability.
“This is a very different profile than the typical growth IPO—Medline is profitable, cash-generative, and well understood, which resonates in the current market.”
— Jeff Zell, Senior Research Analyst, IPO Boutique
Medline’s debt reduction remains a key priority. The company currently carries approximately $17 billion in outstanding debt from its leveraged buyout structure. Proceeds from today’s IPO will be deployed strategically to reduce this burden, improving the company’s balance sheet and optimizing its capital structure for long-term sustainability.
What Lies Ahead: Medline’s Strategic Use of IPO Proceeds
Medline has announced plans to leverage net proceeds of approximately $5.6 billion primarily toward debt reduction. The company’s leveraged capital structure reflects its 2021 $34 billion acquisition financing, which included substantial debt to bridge the difference between the purchase price and equity contributions from the three PE sponsors.
By reducing leverage through this initial public offering, Medline strengthens its financial flexibility for future growth initiatives, acquisitions, or weathering potential healthcare market disruptions. The company will retain capital to fund ongoing operations, innovation in its product lines, and strategic investments that capitalize on growing global demand for medical supplies and healthcare services.
Wall Street and institutional investors now face critical questions about Medline’s long-term trajectory. The company must balance debt reduction with maintaining its competitive edge in medical supplies distribution, expanding internationally, and capitalizing on healthcare trends like aging populations and increased demand for preventive care and protective equipment worldwide.
Sources
- Bloomberg – Medline IPO pricing and market positioning
- Reuters – Historical context and financial metrics
- Medline Newsroom – Official IPO announcements and details
Patrick Graham is a business and finance journalist translating Wall Street’s complexities into stories that matter to everyday readers. With extensive experience in financial journalism and economic analysis, this expert journalist provides sharp insights on market trends, corporate developments, and the economic forces affecting daily life. His reporting helps readers make sense of the business world’s biggest moves.